在二甲双胍控制不佳的2型糖尿病患者中加用吡格列酮与磺脲类药物对心血管事件发生率的影响(TOSCA.IT):一项随机、多中心试验
TOSCA.IT研究在意大利57家糖尿病中心纳入3028例二甲双胍单药控制不佳的2型糖尿病患者,随机加用吡格列酮或磺脲类药物。中位随访57.3个月后,主要复合心血管终点在两组间相似(HR 0.96,95%CI 0.74-1.26,p=0.79),吡格列酮组低血糖事件更少(10% vs 34%,p<0.0001),两组体重平均增加均小于2 kg,心力衰竭、膀胱癌和骨折发生率无显著差异。
要点
- 吡格列酮与磺脲类加用于二甲双胍时,主要心血管复合终点发生率相似(HR 0.96,95%CI 0.74-1.26)。
- 吡格列酮组低血糖发生率低于磺脲类组(148例[10%] vs 508例[34%],p<0.0001)。
- 两组体重平均增加均小于2 kg,心力衰竭、膀胱癌和骨折发生率无显著差异。
核心结论
- 在长期实用性试验中,磺脲类(主要为格列美脲和格列齐特)与吡格列酮作为二甲双胍附加治疗的心血管事件发生率相似。
- 两种广泛可用且经济实惠的治疗在疗效和不良事件方面均为合适选择,尽管吡格列酮与更少的低血糖事件相关。
研究设计与样本
- TOSCA.IT为多中心、随机、实用性临床试验,在意大利57家糖尿病诊所招募50-75岁二甲双胍单药(每日2-3 g)控制不佳的2型糖尿病患者。
- 患者按1:1随机分配,采用区组随机化(区组大小10),按中心和既往心血管事件分层,加用吡格列酮(15-45 mg)或磺脲类(格列本脲5-15 mg、格列美脲2-6 mg或格列齐特30-120 mg,根据当地实践)。
- 试验为非盲设计,但事件裁定者不知晓治疗分配;主要结局采用Cox比例风险模型在改良意向治疗人群中评估。
- 2008年9月18日至2014年1月15日期间,3028例患者被随机分配并纳入分析:1535例分配至吡格列酮,1493例分配至磺脲类(格列本脲24例[2%]、格列美脲723例[48%]、格列齐特745例[50%])。
- 基线时335例(11%)参与者有既往心血管事件;研究基于无效性分析在中位随访57.3个月后提前终止。
主要发现
- 主要结局(全因死亡、非致死性心肌梗死、非致死性卒中或紧急冠状动脉血运重建的复合终点)在吡格列酮组发生105例(1.5/100人年),磺脲类组发生108例(1.5/100人年)(HR 0.96,95%CI 0.74-1.26,p=0.79)。
- 吡格列酮组低血糖发生率低于磺脲类组(148例[10%] vs 508例[34%],p<0.0001)。
- 两组均出现中度体重增加(平均小于2 kg)。
- 心力衰竭、膀胱癌和骨折发生率在治疗组间无显著差异。
临床怎么用
- 作者认为,磺脲类(主要为格列美脲和格列齐特)与吡格列酮作为二甲双胍附加治疗均为合适选择,尽管吡格列酮与更少的低血糖事件相关。
局限性
- 研究基于无效性分析在中位随访57.3个月后提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. METHODS: TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50-75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2-3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and previous cardiovascular events, to add-on pioglitazone (15-45 mg) or a sulfonylurea (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned participants with baseline data available and without any protocol violations in relation to inclusion or exclusion criteria). This study is registered with ClinicalTrials.gov, number NCT00700856. FINDINGS: Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-years) who were given sulfonylureas (hazard ratio 0·96, 95% CI 0·74-1·26, p=0·79). Fewer patients had hypoglycaemias in the pioglitazone group than in the sulfonylureas group (148 [10%] vs 508 [34%], p<0·0001). Moderate weight gain (less than 2 kg, on average) occurred in both groups. Rates of heart failure, bladder cancer, and fractures were not significantly different between treatment groups. INTERPRETATION: In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events. FUNDING: Italian Medicines Agency, Diabete Ricerca, and Italian Diabetes Society.
引用
- Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017. PMID: 28917544. doi:10.1016/S2213-8587(17)30317-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。